GeneTether Therapeutics Inc.
Canadian Securities ExchangeTotal Valuation
GeneTether Therapeutics Inc. carries a market capitalization of 4.65M, placing it among publicly traded companies globally.
| Market Cap | 4.65M |
| Enterprise Value | N/A |
Share Statistics
GeneTether Therapeutics Inc. currently has 38.74M shares outstanding.
| Shares Outstanding | 38.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.92 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | -1.09 |
| P/OCF Ratio | -1.09 |
Financial Position
GeneTether Therapeutics Inc. maintains a current ratio of 34.52, meaning it holds 34.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 34.52 |
| Quick Ratio | 34.52 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -56.45 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
GeneTether Therapeutics Inc.'s stock has gained approximately 140% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.05.
| Beta (5Y) | N/A |
| 52-Week Price Change | 140% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.05 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -750,246.00, while operating income came in at -750,246.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -750,246.00 |
| Pretax Income | -696,961.00 |
| Net Income | -696,961.00 |
| EBITDA | -750,246.00 |
| EBIT | -750,246.00 |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Total book value stands at -466,496.00, with working capital of 986,454.00 providing operational flexibility.
| Cash & Cash Equivalents | 966,108.00 |
| Total Debt | N/A |
| Net Debt | -966,108.00 |
| Equity (Book Value) | -466,496.00 |
| Book Value Per Share | -0.01 |
| Working Capital | 986,454.00 |
Cash Flow
GeneTether Therapeutics Inc. produced -393,179.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -393,179.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -393,179.00 |
| FCF Per Share | -0.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -91.54 |
Scores
GeneTether Therapeutics Inc. posts an Altman Z-Score of 1.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.06 |